CASR and inflammatory bowel disease: We showed that the calcilytic NPS 2143 reduced the clinical symptom score of mice with DSS-induced colitis, suggesting that CaSR inhibition may be a new therapeutic approach for the treatment of IBD to alleviate colitis symptoms [16].